



A webinar series brought to you
by Schwabe Pharma Asia Pacific

How to Make a Difference in Patients with Cognitive Impairment – But No Dementia (yet)

*Industry Mini Session on the occasion of the 35th ECNP Congress with financial support provided by Schwabe Pharmaceuticals.
The content does not necessarily represent the opinion of ECNP.*

Date: 23 Nov 2022 (Wednesday)

Time: 6:00pm – 7:05pm (SGT)

- Introduction
- Broadcast of 35th ECNP Congress Industry Mini Session
 - Prof. Siegfried Kasper, Austria (Chair)
 - Dr. Leonie Visser, The Netherlands (Speaker)
 - Prof. Jakub Hort, Czech Republic (Speaker)
- Live Discussion with Prof. Jakub Hort & PD Dr. Gunnar P.H. Dietz



A webinar series brought to you
by Schwabe Pharma Asia Pacific

Webinar Synopsis

Among older adults, early signs of cognitive decline are often downplayed as “normal aging”. However, persons with purely subjective cognitive or memory impairment or decline [labelled according to various criteria as Subjective Cognitive Impairment (SCI), Subjective Cognitive Decline (SCD), Subjective Memory Impairment (SMI)], or meeting Mild Cognitive Impairment (MCI) criteria with objective deterioration, not only have an elevated risk of developing dementia, but may also be worried and in need of information, advice, alleviation of symptoms and prevention of further cognitive decline. How do you handle patients with SMI, SCI, or MCI? What are the benefits and disadvantages of a formal MCI diagnosis based on detailed and thorough diagnostics? What do patients expect and prefer, and how do you decide which patients should undergo examinations and to what extent? Does evidence support specific diagnostic algorithms? Once diagnosed, what are the most up-to-date treatment recommendations? Top experts in the field provide answers.



A webinar series brought to you
by Schwabe Pharma Asia Pacific

Lecture 1

Mild Cognitive Impairment: The Patient Perspective



Speaker: Dr. Leonie Visser, The Netherlands

Dr. Leonie (N.C.) Visser holds a Master's degree in Medical Psychology from Tilburg University, in the Netherlands. She obtained her PhD cum laude from the University of Amsterdam, Academic Medical Center. Her current research focuses on Medical Communication in memory clinics, aiming to improve clinician-patient communication and develop evidence-based methods and tools to investigate and support communication.

Working at Alzheimer center and the department of Medical Psychology of Amsterdam UMC her ultimate goal is to stimulate patient-centered, personalized medicine in memory clinics for early-stage Alzheimer's disease patients. Since 2020, she is also affiliated to the Center for Alzheimer research at the Karolinska Institute in Stockholm, Sweden. She has become a key expert in medical communication research in the context of Alzheimer's disease and Dementia, currently co-supervising six PhD students. ORCID account: <https://orcid.org/0000-0003-3487-7938>



A webinar series brought to you
by Schwabe Pharma Asia Pacific

Lecture 2

Beginning Cognitive Decline: Current Treatment Recommendations & Recent Data



Speaker: Prof. Jakub Hort, Czech Republic

Prof. Jakub Hort MD, Ph.D., FEAN is Professor of neurology at Charles University and Motol University Hospital, Prague, Czech Republic. He is PI of the Czech Brain Ageing Study, a unique longitudinal prospective study examining early functional, metabolic and structural biomarkers of Alzheimer's Disease and other dementias. Dr. Hort was elected chairman of Section on cognitive neurology of the Czech Neurological Society. He served also as a co-chair of the European Academy of Neurology Scientist Panel Dementia and Cognitive Neurology (2015-2019). Dr. Hort authorized European guidelines on Alzheimer disease and participated in EAN guidelines on non-Alzheimer dementias and combination therapy for Alzheimer disease. Dr. Hort's work indicated that spatial navigation testing can identify MCI and AD. Recently Dr. Hort has been involved in numerous initiatives to bring artificial intelligence, virtual reality and blockchain to both AD research and clinical practice.



A webinar series brought to you
by Schwabe Pharma Asia Pacific



Chair: Prof. Siegfried Kasper, Austria

Dr. Siegfried Kasper is Professor Emeritus of Psychiatry and former Chairman of the Department of Psychiatry and Psychotherapy at the Medical University of Vienna, Austria. He has published more than 600 publications and more than 250 books or book chapters in various areas of psychiatry. He concentrates on the biological bases of mental disorders and their possible treatment approaches. Dr Kasper is a frequent speaker and continues to be actively involved in research programmes studying depression, anxiety, psychosis, and dementia. Dr. Kasper serves/served on the executive committees and advisory boards of several international societies, such as the European College of Neuropsychopharmacology (ECNP) and the European Psychiatric Association (EPA). From 2005 to 2009, he was President of the World Federation of Societies of Biological Psychiatry (WFSBP) and has been appointed as Honorary President of the WFSBP in 2013. He was in the Executive Committee of the International College of Neuropsychopharmacology (CINP) for the period of 2012 to 2018 and is now President of this society. Dr. Kasper is also the Chair of the World Psychiatric Association (WPA) Section of Pharmacopsychiatry. He serves on the editorial boards of numerous journals, including The Lancet Psychiatry, CNS Spectrums, Pharmacopsychiatry, Journal of Affective Disorders, European Archives of Psychiatry and Neuroscience. He is Chief-Editor of the International Journal of Psychiatry in Clinical Practice and was Chief-Editor of the World Journal of Biological Psychiatry. As a result of his research expertise, Dr Kasper is the recipient of numerous national and international scientific and public awards, and he has been acknowledged with the Grand Decoration of Honor in Silver for Services to the Republic of Austria.



A webinar series brought to you
by Schwabe Pharma Asia Pacific

Live Discussion



Speaker: PD Dr. Gunnar P.H. Dietz

Gunnar P.H. Dietz, PD, Ph.D. is Senior Manager Global Medical Affairs at Dr. Willmar Schwabe GmbH & Co. KG in Karlsruhe and lecturer at Göttingen University Medical School in Germany. He studied biology at Köln University and at the Max-Planck-Institute for breeding research, followed by research at the Institute for Gene Biological Research Berlin and at The Rockefeller University in New York, where he also gained his Ph.D. in developmental neurobiology. He continued his research at the Neurological University Hospitals at Tübingen and Göttingen, Germany, where he also earned his “Habilitation” and was appointed “Privatdozent” for neurobiology. He left academia in 2008, working as a project manager in drug discovery and developing cellular assays at Lundbeck A/S in Copenhagen, before he joined Schwabe in Karlsruhe, Germany. His over fifty scientific publications mainly focus on mechanisms of neurodegenerative processes.